Bleximenib
Bleximenib (JNJ-75276617) is an orally active and selective menin-KMT2A inhibitor, with IC50 values of 0.1 nM, 0.045 nM, and ≤0.066 nM for humans, mice, and dogs, respectively. Bleximenib can inhibit the proliferation and induce apoptosis and differentiation of tumor cells. Bleximenib can be used in the research of tumors such as leukemia[1][2].
Product Specifications
Product Name Alternative
JNJ-75276617; Menin-MLL inhibitor 24
UNSPSC
12352005
Target
Apoptosis; FLT3; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bleximenib.html
Purity
99.36
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
COCCN(C)CCC[C@@H](N1CC2(C1)CN(C3=NC=NN=C3OC4=C(C=C(C=C4)F)C(N(CC)C(C)C)=O)CC2)C(C)C
Molecular Formula
C32H50FN7O3
Molecular Weight
599.78
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-148669/Bleximenib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-148669/Bleximenib-SDS-MedChemExpress.pdf
Scientific Category
Reference compound1
Clinical Information
Phase 3
CAS Number
[2654081-35-1]
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
